PL4025592T3 - Sprzężone mimetyki hepcydyny do stosowania w leczeniu czerwienicy prawdziwej - Google Patents

Sprzężone mimetyki hepcydyny do stosowania w leczeniu czerwienicy prawdziwej

Info

Publication number
PL4025592T3
PL4025592T3 PL20860676.4T PL20860676T PL4025592T3 PL 4025592 T3 PL4025592 T3 PL 4025592T3 PL 20860676 T PL20860676 T PL 20860676T PL 4025592 T3 PL4025592 T3 PL 4025592T3
Authority
PL
Poland
Prior art keywords
conjugated
treatment
polycythemia vera
hepcidin mimetics
hepcidin
Prior art date
Application number
PL20860676.4T
Other languages
English (en)
Inventor
David Y. Liu
Gregory Thomas Bourne
Roopa TARANATH
Suneel Kumar Gupta
Nishit Bachulal Modi
Original Assignee
Protagonist Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protagonist Therapeutics, Inc. filed Critical Protagonist Therapeutics, Inc.
Publication of PL4025592T3 publication Critical patent/PL4025592T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL20860676.4T 2019-09-03 2020-09-03 Sprzężone mimetyki hepcydyny do stosowania w leczeniu czerwienicy prawdziwej PL4025592T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962895201P 2019-09-03 2019-09-03
US202062983515P 2020-02-28 2020-02-28
US202063020945P 2020-05-06 2020-05-06
US202063059747P 2020-07-31 2020-07-31
PCT/US2020/049244 WO2021046246A1 (en) 2019-09-03 2020-09-03 Conjugated hepcidin mimetics

Publications (1)

Publication Number Publication Date
PL4025592T3 true PL4025592T3 (pl) 2026-03-16

Family

ID=74681239

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20860676.4T PL4025592T3 (pl) 2019-09-03 2020-09-03 Sprzężone mimetyki hepcydyny do stosowania w leczeniu czerwienicy prawdziwej

Country Status (16)

Country Link
US (2) US20210061872A1 (pl)
EP (2) EP4025592B1 (pl)
JP (2) JP7831841B2 (pl)
KR (1) KR20220075343A (pl)
CN (1) CN114729022A (pl)
AU (1) AU2020343328B2 (pl)
BR (1) BR112022003999A2 (pl)
CA (1) CA3152789A1 (pl)
DK (1) DK4025592T3 (pl)
ES (1) ES3058577T3 (pl)
FI (1) FI4025592T3 (pl)
IL (1) IL291030A (pl)
MX (1) MX2022002633A (pl)
PH (1) PH12022550510A1 (pl)
PL (1) PL4025592T3 (pl)
WO (1) WO2021046246A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2968443T3 (da) 2013-03-15 2021-12-06 Protagonist Therapeutics Inc Hepcidinanaloger og anvendelser deraf
PT3143037T (pt) 2014-05-16 2021-09-24 Protagonist Therapeutics Inc Antagonistas peptídicos tioéter de integrina alfa4beta7
US9624268B2 (en) 2014-07-17 2017-04-18 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
EP3749345A4 (en) 2018-02-08 2022-04-06 Protagonist Therapeutics, Inc. CONJUGATED HEPCIDIN MIMETICS
TW202019948A (zh) 2018-07-12 2020-06-01 美商領導醫療有限公司 介白素-23受體之肽抑制劑及其治療發炎疾病之用途
HRP20250769T1 (hr) 2020-01-15 2025-08-29 Janssen Biotech, Inc. Peptidni inhibitori receptora za interleukin-23 i njihova uporaba u liječenju upalnih bolesti
AU2021209086A1 (en) 2020-01-15 2022-08-04 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2021383828A1 (en) 2020-11-20 2023-07-06 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
AU2022249095A1 (en) * 2021-04-01 2023-10-12 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
CA3220871A1 (en) * 2021-06-14 2022-12-22 Protagonist Therapeutics, Inc. Hepcidin mimetics for treatment of hereditary hemochromatosis
WO2023288019A2 (en) 2021-07-14 2023-01-19 Janssen Biotech, Inc. Lipidated peptide inhibitors of interleukin-23 receptor
EP4472996A4 (en) * 2022-02-02 2025-11-26 Protagonist Therapeutics Inc Conjugated hepcidin mimetics
EP4472995A4 (en) * 2022-02-02 2025-11-19 Protagonist Therapeutics Inc Conjugated hepcidin mimetics
WO2024011188A1 (en) * 2022-07-07 2024-01-11 Protagonist Therapeutics, Inc. Combination therapy for treatment of iron overload diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
EP1956000B1 (en) 1999-03-17 2016-10-05 Novo Nordisk A/S Acylating agents useful for acylating peptides
US7094785B1 (en) * 2002-12-18 2006-08-22 Cornell Research Foundation, Inc. Method of treating polycythemia vera
AU2008216265B2 (en) 2007-02-15 2014-04-03 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
DK2968443T3 (da) 2013-03-15 2021-12-06 Protagonist Therapeutics Inc Hepcidinanaloger og anvendelser deraf
US9315545B2 (en) 2014-04-07 2016-04-19 Merganser Biotech, Inc. Hepcidin mimetic peptides and uses thereof
KR20170043509A (ko) * 2014-06-27 2017-04-21 프로타고니스트 테라퓨틱스, 인코포레이티드 헵시딘 및 미니-헵시딘 유사체 및 그의 용도
CA3002416C (en) 2015-10-23 2023-10-24 Vifor (International) Ag Benzimidazolyl derivatives for use as ferroportin inhibitors
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
CA3035234A1 (en) 2016-09-06 2018-03-15 La Jolla Pharmaceutical Company Methods of treating iron overload
WO2018128828A1 (en) 2016-12-23 2018-07-12 Bayer Healthcare Llc Novel hepcidin mimetics and uses thereof
EP3749345A4 (en) * 2018-02-08 2022-04-06 Protagonist Therapeutics, Inc. CONJUGATED HEPCIDIN MIMETICS

Also Published As

Publication number Publication date
WO2021046246A1 (en) 2021-03-11
AU2020343328A1 (en) 2022-04-07
ES3058577T3 (en) 2026-03-11
US20210061872A1 (en) 2021-03-04
EP4706671A3 (en) 2026-04-01
EP4025592A1 (en) 2022-07-13
JP2022546878A (ja) 2022-11-09
PH12022550510A1 (en) 2023-09-04
EP4706671A2 (en) 2026-03-11
AU2020343328B2 (en) 2026-04-09
BR112022003999A2 (pt) 2022-05-31
CN114729022A (zh) 2022-07-08
EP4025592B1 (en) 2025-10-29
CA3152789A1 (en) 2021-03-11
IL291030A (en) 2022-05-01
KR20220075343A (ko) 2022-06-08
MX2022002633A (es) 2022-06-02
US20220372099A1 (en) 2022-11-24
FI4025592T3 (fi) 2026-01-30
EP4025592A4 (en) 2023-08-02
JP7831841B2 (ja) 2026-03-17
JP2025163134A (ja) 2025-10-28
DK4025592T3 (da) 2026-02-09

Similar Documents

Publication Publication Date Title
PL4025592T3 (pl) Sprzężone mimetyki hepcydyny do stosowania w leczeniu czerwienicy prawdziwej
IL289975A (en) Use of cannabidiol in the treatment of dravet syndrome
IL282487A (en) Tyk2 inhibitors and uses thereof
SI3661954T1 (sl) Muteini interlevkina-21 in postopki zdravljenja
SI3658557T1 (sl) Zaviralci TYK2 in njihova uporaba
HUE058931T2 (hu) Pilokarpin hidroklorid alkalmazása presbyopia kezelésére
EP3908270A4 (en) COMBINATION OF DEXTROMETHORPHANE AND BUPROPION FOR THE TREATMENT OF DEPRESSION
IL276609A (en) Combined treatment with epilimod and glutamatergic factors
PL3889145T3 (pl) 8-cyjano-5-piperydyno-chinoliny jako antagoniści TLR7/8 oraz ich zastosowanie w leczeniu zaburzeń immunologicznych
SI3716992T1 (sl) Uporaba antagonistov VEGF za zdravljenje angiogenih očesnih motenj
PL3972643T3 (pl) Antagoniści układu dopełniacza do stosowania w sposobach leczenia neuropatii paraproteinemicznych
IL261721A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors
MX2019001669A (es) Metodos y composiciones para el tratamiento de trastornos epilepticos.
IL286248A (en) Tyk2 inhibitors and uses thereof
PL3325509T3 (pl) Przeciwciała anty-TfR oraz ich zastosowanie w leczeniu zaburzeń proliferacyjnych i zapalnych
PL3806898T3 (pl) Antagonista gremlin-1 do zastosowania w leczeniu nowotworu
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
PT3481846T (pt) 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda
PL3658140T3 (pl) Połączenia aprocitentanu z dodatkowymi składnikami czynnymi do leczenia opornego nadciśnienia
PL3768284T3 (pl) Kompozycje z fageliny entrecoccus do zastosowania w terapii
IL283511A (en) Dendrimer for therapy and imaging
PL3592355T3 (pl) Kx2-391/kx-01 do zastosowania w leczeniu rogowacenia słonecznego
IL287704A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
PT3773589T (pt) Inibidor de ret para utilização no tratamento de cancro com alteração de ret
PL3732294T3 (pl) Tymohydrochinon do stosowania w leczeniu hiperglikemii